TG101348, a JAK2-selective antagonist, inhibits pr...[Leukemia. 2008] - PubMed Result

SearchDatabase nameforSearch term

Advanced Search (beta)

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Leukemia. 2008 Sep;22(9):1790-2. Epub 2008 Mar 20. Links

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.

Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A.

PMID: 18354492 [PubMed - in process]

Related Articles

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. [Leukemia. 2008]
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. [Leukemia. 2007]
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. [Blood. 2008]
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. [Cancer Cell. 2008]
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. [N Engl J Med. 2007]
» See all Related Articles...

Display Show